{"url_path":"/sec/trda/8-k/2026-05-19/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1689375/0001104659-26-063325-index.html","accession_number":"0001104659-26-063325","cik":"0001689375","ticker":"TRDA","issuer_name":"Entrada Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1689375/0001104659-26-063325-index.html","primary_entity_key":"0001689375","primary_entity_name":"Entrada Therapeutics, Inc."},"word_count":96,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\nThe following exhibit relating to Item 7.01 of this Current Report\nshall be deemed to be furnished and not filed:\n\n \n\n[99.1](tm2614944d1_ex99-1.htm)\n[Corporate Presentation of Entrada Therapeutics, Inc., dated May 2026.](tm2614944d1_ex99-1.htm)\n\n104\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n** **\n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nEntrada Therapeutics, Inc.\n\n \n \n\nDate: May 18, 2026\n/s/ Dipal Doshi\n\n \nDipal Doshi\n\n \nChief Executive Officer\n\n \n\n \n\n** **"}